Genelux (NASDAQ:GNLX) Reports Quarterly Earnings, Falls Short of Expectations

Genelux (NASDAQ:GNLX) shared its quarterly earnings results on Friday, revealing earnings per share (EPS) of ($0.26) for the quarter. This figure missed the consensus expectation of ($0.19) by $0.07, as reported by Zacks.

Genelux Stock Performance

On Friday, shares of Genelux opened at $3.08. The company has a moving average price of $4.06 over the last 50 days and a moving average price of $3.10 over the last 200 days. The stock has experienced a twelve-month low of $1.60 and a high of $6.50. Currently, Genelux has a market capitalization of $106.38 million, with a price-to-earnings (P/E) ratio of -3.24 and a beta of -1.41.

Expert Analysis

In a separate analysis, HC Wainwright maintained a "buy" rating for Genelux and set a target price of $30.00 per share in a report released on Tuesday. Out of five equity research analysts, four have rated the stock as a buy, while one assigned a strong buy rating. According to MarketBeat.com data, Genelux holds an average rating of "Buy" with an average price target of $18.25.

About Genelux

Genelux Corporation is a clinical-stage biopharmaceutical company focused on developing innovative oncolytic viral immunotherapies aimed at treating aggressive and challenging solid tumors. The company's leading product, Olvi-Vec, is a proprietary strain of the vaccinia virus designed for use against ovarian cancer and non-small cell lung cancer.

Other Insights

Investors might want to consider their options carefully. While analysts have rated Genelux positively, they also highlight other opportunities in the market. A review of top-rated stocks suggests that there may be five other stocks that analysts believe could be better investments at this time.

Conclusion

The performance of Genelux in its latest earnings report showcases the challenges it faces in meeting market expectations. As a biopharmaceutical company, its success hinges on the development and approval of its therapies.

earnings, finance, stocks, biopharmaceutical, investment